Difference between revisions of "Opioids"
Line 11: | Line 11: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
+ | |||
+ | Opiods act on opioid (OP) receptors. OP receptors are G-protein coupled: activation of the receptors causes inhibition of adenylate cyclase, decreasing cAMP levels within the cell. Thus, receptor-ligand interaction promotes the opening of K<sup>+<sup> channels within the plasma membrane, and also inhibits that of voltage-gated calcium channels. There are three types of opioid receptors: | ||
+ | * '''OP1''': These are located spinally and supraspinally. The primary effect of receptor engagement is sedation. | ||
+ | * '''OP2''': Located spinally, the main effect of OP2 activation is sedation. | ||
+ | * '''OP3''': OP3 receptor interaction gives rise to analgesia, on a spinal and supraspinal level. | ||
==Pharmacokinetic Considerations== | ==Pharmacokinetic Considerations== |
Revision as of 11:49, 3 March 2009
The opioid drugs include morphine and its synthetic derivatives. They are powerful analgesics, and have dose-dependent sedative properties.
Opioids have additional recognised effects. They:
- Decrease the sensitivity of the respiratory centres of the brain to carbon dioxide.
- Give potent cough suppression.
- Cause emesis.
- Constrict the pupils (miosis).
- Reduce gastro-intestinal motility.
- Lead to histamine release.
Mechanism of Action
Opiods act on opioid (OP) receptors. OP receptors are G-protein coupled: activation of the receptors causes inhibition of adenylate cyclase, decreasing cAMP levels within the cell. Thus, receptor-ligand interaction promotes the opening of K+ channels within the plasma membrane, and also inhibits that of voltage-gated calcium channels. There are three types of opioid receptors:
- OP1: These are located spinally and supraspinally. The primary effect of receptor engagement is sedation.
- OP2: Located spinally, the main effect of OP2 activation is sedation.
- OP3: OP3 receptor interaction gives rise to analgesia, on a spinal and supraspinal level.
Pharmacokinetic Considerations
Side Effects and Contraindications
Drugs in this Group
Morphine
Buprenorphine
Butorphanol
Pethidine
Methadone
Fentanyl
Etorphine
Opioid Antagonists
Naloxone is an antagonist to endogenous opioids. It is frequently used in human medicine to antagonise opioid narcotics in the incidence of overdose. Naloxone may be administered intravenously, intramuscularly, intrathecally or subcutaneously. It has a short duration of action (1-2 hours) and so repeated administrations may be necessary.